No headlines found.
Aethlon Medical Announces Pricing of $4.7 Million Public Offering
PRNewswire (Wed, 15-May 9:15 AM ET)
Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Aethlon Medical trades on the NASDAQ stock market under the symbol AEMD.
As of May 29, 2024, AEMD stock price declined to $0.42 with 3,879,251 million shares trading.
AEMD has a beta of 0.39, meaning it tends to be less sensitive to market movements. AEMD has a correlation of 0.00 to the broad based SPY ETF.
AEMD has a market cap of $2.13 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AEMD stock traded as high as $124.90 and as low as $.37.
The top ETF exchange traded funds that AEMD belongs to (by Net Assets): VXF.
AEMD has underperformed the market in the last year with a price return of -86.5% while the SPY ETF gained +26.9%. AEMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -75.7% and -50.6%, respectively, while the SPY returned +4.2% and +0.5%, respectively.
AEMD support price is $.39 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEMD stock will trade within this expected range on the day.